Balance Sheet: Liabilities and Stockholders’ Equity
The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.
Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.
Paying user area
Try for free
Vertex Pharmaceuticals Inc. pages available for free this week:
- Statement of Comprehensive Income
- Common-Size Income Statement
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Solvency Ratios
- Common Stock Valuation Ratios
- Selected Financial Data since 2005
- Net Profit Margin since 2005
- Operating Profit Margin since 2005
- Return on Assets (ROA) since 2005
- Debt to Equity since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Vertex Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Vertex Pharmaceuticals Inc., consolidated balance sheet: liabilities and stockholders’ equity
US$ in thousands
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
Total liabilities exhibited a consistent upward trend from 2021 to 2025, increasing from US$3,332.5 million to US$6,977.2 million. This growth was mirrored by a corresponding increase in total shareholders’ equity, rising from US$10,100 million in 2021 to US$18,665.8 million in 2025, although with a slight decrease between 2023 and 2024. Consequently, the overall size of the company, as measured by total liabilities and shareholders’ equity, expanded significantly over the five-year period.
- Current Liabilities
- Current liabilities demonstrated substantial growth between 2021 and 2023, increasing from US$2,142 million to US$3,547.4 million. While the rate of increase slowed in 2024 and 2025, current liabilities remained elevated, reaching US$3,861.2 million. A significant component of this growth was accrued expenses, which nearly doubled from US$1,678.6 million in 2021 to US$2,971.2 million in 2025. Other current liabilities also contributed significantly to the increase, more than doubling from US$268.4 million to US$428.3 million. The introduction of foreign currency forward contracts in 2025, totaling US$79.4 million, represents a new element within current liabilities.
- Long-Term Liabilities
- Long-term liabilities experienced a more dramatic increase than current liabilities, growing from US$1,190.5 million in 2021 to US$3,116 million in 2025. This increase was largely driven by a substantial rise in long-term operating lease liabilities, which increased from US$377.4 million to US$1,846.5 million over the period. Tax-related liabilities also increased significantly, from no value in 2021 to US$895.4 million in 2025. Long-term finance lease liabilities decreased over the period, falling from US$509.8 million to US$106.7 million.
- Shareholders’ Equity
- Shareholders’ equity increased steadily from 2021 to 2023, rising from US$10,100 million to US$17,580.4 million. A slight decrease was observed in 2024, to US$16,409.6 million, before recovering to US$18,665.8 million in 2025. This growth was primarily fueled by an increase in retained earnings, which more than tripled from US$3,200.8 million in 2021 to US$13,560 million in 2025. Additional paid-in capital decreased from US$6,880.8 million in 2021 to US$5,119.2 million in 2025. Accumulated other comprehensive income (loss) fluctuated, moving from a positive US$15.9 million in 2021 to a negative US$15.9 million in 2025.
- Specific Accruals
- Product revenue accruals represent a substantial portion of total liabilities, increasing from US$847.4 million in 2021 to US$1,814.1 million in 2025. Payroll and benefits accruals also showed consistent growth, rising from US$191.3 million to US$397.7 million over the same period. Tax related accruals were volatile, decreasing from US$211.3 million in 2021 to US$99.5 million in 2023, then increasing to US$103.1 million in 2025. Capital related accruals were not present in 2021 and 2022, but grew to US$86.0 million in 2025.
In summary, the company experienced significant growth in both liabilities and shareholders’ equity between 2021 and 2025. The increase in liabilities was driven by growth in both current and long-term obligations, particularly accrued expenses and operating lease liabilities. Shareholders’ equity growth was primarily attributable to increased retained earnings, indicating profitability. The fluctuations in certain accrual accounts warrant further investigation to understand the underlying business drivers.